Gmt Capital Corp Allovir, Inc. Transaction History

Gmt Capital Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.15 - $3.64 $230,488 - $390,222	107,204 Added 2.61%	4,211,283 $9.05 Million
Q2 2023 Aug 10, 2023	BUY	$3.17 - $5.82 $2.44 Million - $4.48 Million	770,433 Added 23.11%	4,104,079 $14 Million
Q1 2023 May 09, 2023	BUY	$3.94 - $7.05 $2.26 Million - $4.05 Million	574,800 Added 20.83%	3,333,646 $13.1 Million
Q3 2022 Nov 10, 2022	BUY	$4.13 - $8.79 $3.58 Million - $7.63 Million	867,676 Added 45.88%	2,758,846 $21.8 Million
Q2 2022 Aug 10, 2022	BUY	$3.26 - $7.06 $2.46 Million - $5.32 Million	753,100 Added 66.17%	1,891,170 $7.38 Million
Q1 2022 May 11, 2022	BUY	$6.75 - $13.52 $3.15 Million - $6.3 Million	466,300 Added 69.41%	1,138,070 $7.68 Million
Q4 2021 Feb 11, 2022	BUY	$12.94 - $25.99 $2.53 Million - $5.08 Million	195,282 Added 40.98%	671,770 $8.69 Million
Q3 2021 Nov 09, 2021	BUY	$16.97 - $25.06 $8.09 Million - $11.9 Million	476,488 New	476,488 $11.9 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.